Belite Bio (BLTE) EBT (2022 - 2026)

Belite Bio (BLTE) has reported EBT for 5 consecutive years, with -$26.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBT fell 88.68% year-over-year to -$26.9 million; the TTM figure through Mar 2026 stood at -$63.4 billion (down 123.99% YoY), while the FY2025 annual figure was -$75.0 million, down 107.64% from the prior year.
• EBT came in at -$26.9 million for Q1 2026 at Belite Bio, up from -$25.3 billion in the prior quarter.
• The five-year high for EBT was -$6.8 million in Q4 2022, with the low at -$25.3 billion in Q4 2025.
• Average EBT over 5 years is -$7.4 billion, with a median of -$6.8 billion recorded in 2023.
• Across the five-year window, EBT slumped 144371.46% in 2024 and jumped 99.82% in 2025, its largest moves.
• Year by year, EBT stood at -$6.8 million in 2022, then declined by 3.07% to -$7.0 million in 2023, then plunged by 144371.46% to -$10.1 billion in 2024, then slumped by 150.73% to -$25.3 billion in 2025, then jumped by 99.89% to -$26.9 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$26.9 million, -$25.3 billion, and -$21.7 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.